OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate ...
Lilly inks a global licensing deal with OliX for OLX75016, a Phase 1 candidate targeting MASH and other cardiometabolic conditions. Get real-time earnings alerts before the market moves and access ...
SEONGNAM, South Korea, February 10, 2025--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with ...
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals ...
Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its pipeline for the disease ...
Overcoming these problems with its unique gene-silencing technology is OliX Pharmaceuticals, a clinical-stage/pure-play RNAi-therapeutics company that is changing the paradigm of RNAi-therapeutic ...
OliX Pharmaceuticals, the first Asian company to advance its own proprietary RNA interference (RNAi) technology platform into the clinic, is using RNAi technology to treat skin, eye and lung ...
OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and Company (“Lilly”). This collaboration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback